NIH Awards Mount Sinai Researchers $12 Million to Personalize Sickle Cell Treatment
Study aims to learn which therapies work best for whom
The Mount Sinai Health System has received a $12,180,625 grant from the National Heart, Lung and Blood Institute to compare new treatment options for sickle cell disease and determine which work best for specific patients.
“Sickle cell traditionally has been a neglected disease, but it benefited from a flurry of innovation over the last decade and there are now three new medications approved for the disease,” says Jeffrey Glassberg, MD, Director of the Mount Sinai Sickle Cell Program.
“While this is welcome news, clinicians now have a new challenge. No studies have compared the drugs to each other or looked at their use in combination, so there’s very little information to help decide which of the new drugs are best for which patients.”
The study, known as REAL (Registry Expansion Analyses to Learn) Answers, is a collaboration among 10 sickle cell centers across the United States that will implement a novel observational study approach called target trial emulation. This approach enables researchers to gain, within five years, knowledge that is equivalent to dozens of randomized trials.
“We hope to accomplish a century worth of research in a single grant cycle,” Dr. Glassberg says. “Patients need answers now.”
The study will enroll and collect data from 1,200 sickle cell patients using a structure similar to that of a clinical trial, including blood draws, tracking hospital admissions, and documenting drug administration and adverse events. The researchers will also explore genetic predictors of response to medications, so that clinicians will be able to provide more personalized treatment plans based on each patient's genetic makeup as well as their other unique characteristics.
“Hydroxyurea, the only drug available to treat sickle cell disease until 2017, was initially approved for people who had severe pain crises,” Dr. Glassberg explains. “We found out 20 years after its approval that the drug actually improves organ function and prolongs life, but we had only been giving it to people in pain, which is not everyone. I don’t want that to happen again with these new drugs. We’re going to investigate all of them, individually and in combination, so we can give the right drug to the right patient immediately, and don’t repeat our past mistakes.”
The study will be led by Dr. Glassberg in collaboration with co-Principal Investigator Abdullah Kutlar, MD, of the Medical College of Georgia. Additional partners in the project include Duke University, Medical University of South Carolina, St. Jude Children’s Research Hospital, University of Illinois at Chicago, Washington University in St. Louis, University of California San Francisco, Research Triangle International, and Tufts University.
About the Mount Sinai Health System
Mount Sinai Health System is one of the nation’s leading integrated academic health systems and one of the largest in the New York metropolitan area. The Health System includes approximately 48,000 employees, more than 9,000 physicians, and 8,600 nurses across seven hospitals, more than 400 outpatient practices, over 600 research and clinical laboratories, a school of nursing, and schools of medicine and graduate school of biomedical sciences.
As a leading learning health system, Mount Sinai combines clinical expertise with scientific discovery to improve patient care while training the next generation of health care and biomedical leaders. The Health System provides care across every stage of life, from prenatal care through geriatrics, while advancing personalized medicine through artificial intelligence, data science, and biomedical research.
Mount Sinai is consistently recognized among the nation’s leading academic health systems for patient care, research, and education. The Mount Sinai Hospital is ranked No. 1 in New York and recognized as one of the world’s top Smart Hospital by Newsweek. The Icahn School of Medicine at Mount Sinai ranks No. 11 among U.S. medical schools for National Institutes of Health (NIH) funding and No. 1 among freestanding medical schools, reflecting the strength of its scientific enterprise and leadership in biomedical research.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Instagram, LinkedIn, X, and YouTube. To listen to news and stories from Mount Sinai, visit the Mount Sinai Podcast Network.